Scientific Articles COVID-19 articles

Coronavirus y corazón ¿Cómo deben prepararse los cardiólogos?

Convalescent Plasma for Severe Pneumonia from COVID-19

Convalescent Plasma for Severe Pneumonia from COVID-19

After testing multiple drugs and drug combinations in COVID-19 patients, only Remdesivir – for hospitalized patients – and dexamethasone – in patients requiring Oxygen – have shown some benefits.  Convalescent plasma has been used for years assuming passive immunization might help control the infection until a specific immune response is established in the infected person.

Historia natural de la infección asintomática por COVID-19

Natural History of Asymptomatic COVID-19 Infection

Information on the natural history of asymptomatic infection with the new coronavirus (COVID-19) remains scarce. We are just beginning to understand what happens with patients with severe disease. The outbreak of COVID-19 on the cruise ship Diamond Princess provided a unique opportunity to study contacts and patients with asymptomatic infection within a closed population. This

Efficacy of Remdesivir against COVID-19

This final report published in NEJM about the efficacy of remdesivir against COVID-19 infection vs placebo showed its superiority though only in soft end points, which does not seem to modify the course of this pandemic. Multiple drugs initially promising have been shown ineffective against the new virus. The case of hydroxychloroquine resulted paradigmatic: not

Historia natural de la infección asintomática por COVID-19

Long-Term Cardiovascular Effects of COVID-19

In many places worldwide, the worst part of the pandemic is still to come. Meanwhile, in other areas, the number of cases is rising again. In this context, the long-term effects of COVID-19 are starting to show. Many believe this is not a current issue, but it will definitely be a problem in the future.

Historia natural de la infección asintomática por COVID-19

LATAM: Information on the Impact of the Pandemic with a Focus on MI

There are several studies from all corners of the world (China, Europe, USA) presenting data on the impact of COVID19 on interventional cardiology in general, and on MI in particular. What is new about this study is that it presents data on LATAM and that it has been published in an international magazine.  Seldom do

Historia natural de la infección asintomática por COVID-19

Myocardial Injury for COVID-19 Even in Young Patients with Mild Symptoms

Most young COVID-19 patients not requiring hospitalization showed abnormal cardiac magnetic resonance imaging (CMR) beyond two months after diagnosis. Myocardial injury had been found in more serious cases, but not in a healthy population recovered at home. The increasing evidence of the virus’ capacity to directly affect the heart across the whole population and disease

Infarction, Stroke and Aortic Emergency Syndromes in the Shadow of the Pandemic

The coronavirus pandemic has had a negative impact on the most pressing cardio and neurological emergencies, such as strokes or aortic dissection. These emergencies are normally treated in high complexity centers, which is why it is relatively simple to analyze the number of transfers before and after the pandemic.  For some time, care centers have

Recomendaciones de la ACC con el nuevo coronavirus

When and How Could Dexamethasone Be Useful in a COVID-19 Infection?

More details have emerged on the group of COVID-19 patients who received dexamethasone in the RECOVERY trial. These data, published as a preliminary report in the New England Journal of Medicine (NEJM), suggest that dexamethasone could reduce mortality in cases when infection effects are mainly derived from immunopathological elements in patients requiring mechanical ventilation or

Coronavirus y corazón ¿Cómo deben prepararse los cardiólogos?

Rapid Drop of Antibodies in Mild COVID-19 patients

A fast drop in COVID-19 antibodies in mild patients triggers the alarm for protection against the new virus. This decrease, observed within the first 90 days after contagion, might slow down over time. However, it calls for caution when it comes to the feeling of “protection” in recovered patients, vaccine immunization at long-term, and ultimately

Trombólisis local en tromboembolismo pulmonar

COVID-19 PE: Nontraditional Risk Factors?

Risk factors for pulmonary embolism (PE) among patients with the new coronavirus are different from those traditionally observed. A French study recently published in Eur Heart J showed those new risk factors, and also that the risk of PE is reduced by the use of anticoagulant agents, just like in patients with conventional risk factors.

Coronavirus y corazón ¿Cómo deben prepararse los cardiólogos?

Vasculitis, Thrombosis and Angiogenesis: Covid-19´s Unique Patters

In this small, yet interesting series, we observe angiogenesis could differentiate pulmonary physiopathology by Covid-19 vs. from viral infections of similar severity (such as influenza). Being quite small, we can hardly consider it universal, or whether it could have clinical impact. Meanwhile, we keep learning about the new virus.  Progressive respiratory failure is the main